ZIP1642

ZIP1642 is a lipid nanoparticle-formulated, dual-antigen self-amplifying RNA (saRNA) vaccine candidate for COVID-19 developed by Ziphius Vaccines. It encapsulates two separate saRNA constructs encoding the SARS-CoV-2 spike receptor-binding domain (S-RBD) and nucleocapsid (N) protein in a single LNP, enabling in situ amplification of RNA and prolonged antigen expression at low doses. Preclinical studies in mice and hamsters have shown that intramuscular prime-boost immunization with ZIP1642 elicits high titers of neutralizing antibodies against multiple SARS-CoV-2 variants (including Wuhan-like, Beta, Delta, and reduced but detectable responses to Omicron), as well as robust Th1-biased CD4+ and CD8+ T cell responses specific for both S and N antigens, leading to reduced viral loads, lung pathology, and inflammatory markers after challenge. ZIP1642 is positioned as a next-generation multi-antigen saRNA COVID-19 vaccine, but to date its development has remained in the preclinical stage.